RxDoctor Payments Data

Vikyath Prakash, MD

Nephrology · Dallas, TXNPI 1255665402

Payments from drug & device makers

$33,853in general payments, 2019–2025

Across 204 payments — averaging $165.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aurinia Pharma U.S., Inc.$16K
  • Travere Therapeutics, Inc.$7K
  • Calliditas Therapeutics US Inc.$6K
  • AstraZeneca$2K
  • Vifor Pharma, Inc.$579
  • Amgen$521
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$3,68611%
  • Speaking & faculty fees$21,25063%
  • Travel & lodging$3,31710%
  • Food & beverage$5,48716%
  • Education$1130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,853 in reported general payments places this provider in the 85th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$313,949
Medicare patients
524
Services billed
3,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol116$101,263
JardianceEmpagliflozin88$70,121
KerendiaFinerenone64$58,568
VeltassaPatiromer Calcium Sorbitex30$27,091
LokelmaSodium Zirconium Cyclosilicate23$19,241
EntrestoSacubitril/Valsartan11$13,914
GemtesaVibegron15$11,540
MyrbetriqMirabegron11$4,842
Sevelamer Carbonate44$4,707
Torsemide188$4,084
Nifedipine ErNifedipine104$2,985
Cinacalcet Hcl23$2,671
Candesartan Cilexetil37$2,375
Losartan Potassium237$2,196
Midodrine Hcl19$2,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$2,290$120,504139 claims
Boehringer IngelheimJardiance$28$70,12188 claims
BayerKerendia$479$58,56864 claims
NovartisEntresto$45$13,91411 claims
ANI Pharmaceuticals, Inc.Valsartan$66$69028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →